Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Gynecologic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Recurrence 2Neoplasms 2Triple Negative Breast Neoplasms 1Sarcoma 1Prostatic Neoplasms 1Ovarian Neoplasms 1Multiple Myeloma 1Head and Neck Neoplasms 1Esophageal Neoplasms 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cisplatin 90Fluorouracil 76Radiotherapy 63Paclitaxel 58Docetaxel 49Oxaliplatin 48Irinotecan 42Leucovorin 32Capecitabine 31Carboplatin 27Radiation 21Surgical Procedures, Operative 20Esophagectomy 20pembrolizumab 15Neoadjuvant Therapy 15Bevacizumab 15Cetuximab 13Drug Therapy 12Epirubicin 11Chemotherapy, Adjuvant 9S 1 (combination) 8Magnetic Resonance Spectroscopy 8Gemcitabine 8Trastuzumab 7Nivolumab 7Erlotinib Hydrochloride 7Surveys and Questionnaires 6Panitumumab 6Immunohistochemistry 6Chemoradiotherapy 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Esophageal Neoplasms × CLR1404 × Clear all
NCT01495663 2015-02-26

Dose Escalation Study of I-131-CLR1404 in Subjects With Cancer That Does Not Respond to Treatment or Has Returned

Cellectar Biosciences, Inc.

Phase 1 Completed
12 enrolled
BreastGastrointestinalGenitourinaryGynecologicSarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Recurrence, Sarcoma, Colorectal Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡